From Python Blood to Profit

Humans have a habit of turning other animals into pharmacies.

First we study them. Then we patent whatever we can extract from their bodies, their secretions, or the metabolic tricks evolution handed them. And then, if the product works, we call it innovation.

The latest example comes from python blood.

Researchers studying Burmese pythons identified a molecule called para-tyramine-O-sulphate, or pTOS, which surges after these snakes eat. In the new paper, the authors describe pTOS as the most dramatically induced metabolite they found, rising by more than 1,000-fold after feeding. They also report that chronic pTOS treatment in diet-induced obese male mice reduced food intake and produced a 9% vehicle-adjusted reduction in body weight over 28 days. The findings were published in Nature Metabolism on the 19th March 2026.

That is the headline. “Python blood could pave the way for new obesity drugs.” It sounds futuristic, clever, almost elegant. Nature inspiring medicine once again. But there are at least three different stories hiding inside it, and only one of them is getting the glossy treatment.

The first is the obvious one: scientists may have found a metabolite involved in appetite regulation that works differently from the current crop of weight-loss drugs. Stanford Medicine says pTOS appears to act through neurons in the hypothalamus, the brain region involved in regulating feeding behaviour. In mice, the study found that pTOS suppressed food intake without affecting water intake, energy expenditure, or locomotion, and did not induce conditioned flavour avoidance, which matters because that is one way researchers try to detect whether an appetite-suppressing intervention is simply making animals feel unwell.

The second story is about how badly humans want a pharmaceutical answer to a problem we created.

Obesity does not exist in a vacuum. It exists in a world saturated with fast food, engineered hyper-palatability, relentless marketing, sedentary infrastructure, poverty, stress, sleep disruption, and a food culture so warped that people are taught to chase protein bars while ignoring beans. So naturally, instead of asking what sort of society keeps generating metabolic dysfunction at scale, we keep asking which molecule, venom, hormone, peptide, or reptile might rescue us from the consequences.

And the third story, the one routinely pushed offstage, is this: even when the science sounds exciting, humans still reach for the same old model of domination. Study the snake. Isolate the molecule. Inject the mice. Build the company. Sell the solution. That is exactly what happened here.

The researchers were studying the extreme feast-and-famine biology of pythons, animals that can fast for extended periods and then consume huge meals. The paper notes that Burmese pythons can fast for 12 to 18 months and can consume prey equal to their own body weight in a single meal. In the laboratory arm of the study, pythons were fasted for 28 days, then fed meals equal to around 20 to 25% of their body weight before blood and tissue collection. The mice, meanwhile, were used to test whether pTOS altered feeding behaviour and body weight. Some of the pythons were killed under anaesthesia for sample collection. The mice were deliberately made obese through a high-fat diet before daily injections during the chronic treatment phase.

This is what animal use defenders always want us to ignore. The “discovery” is presented as if it floated down from the heavens. As if the only morally relevant fact is the possible outcome for humans. As if the python is just an exotic clue and the mice are just a procedural footnote.

Call it translational science, metabolic research, or drug discovery, and people are trained not to see the individuals being used. The language does the laundering. A python becomes a model of extreme physiology. A mouse becomes a diet-induced obesity model. A brain becomes a feeding pathway. A body becomes data. Once that shift happens, the moral question is treated like an annoyance rather than the starting point.

And yet even within that system, the findings are more limited than the headlines imply.

This is not a new obesity drug. It is not a proven human therapy. It is not even evidence that pTOS will work meaningfully in humans. The researchers found pTOS in human blood after meals too, but the rise was much smaller in most datasets than in pythons. Stanford noted that in five of six public human datasets, pTOS increased after eating, generally by about two- to fivefold. One person showed a much larger rise, but even the researchers could not say whether that translated to greater fullness or lower food intake. The next step, by their own account, is to identify the molecular targets in the brain and determine whether this pathway can be engaged in humans.

In other words, the usual pattern applies. Early animal findings are dressed up as imminent therapeutic hope, the media runs with the most marketable angle, and the public is left with the impression that the suffering built into the process is not only normal but necessary.

Maybe pTOS will eventually help some humans. Maybe it will inspire a useful class of drugs. But there is something bleakly familiar about the route we keep taking. Humans design food systems that wreck health, then scour the bodies of other animals for compounds that might mitigate the issue, all while pretending this is simply neutral progress rather than a civilisation eating its own tail.

There is also a deeper irony here. Pythons are being framed as “metabolic superheroes” because they can do what humans cannot: go long periods without eating, process enormous meals, remodel their physiology, and remain functional. That is fascinating. It is also a reminder that other animals are not crude prototypes for us. They are not unfinished humans. They are not raw material for our drug pipeline. They are their own kinds of beings, shaped by evolutionary pressures utterly different from ours. But human supremacy has a way of flattening every encounter into use.

If a snake has a molecule we like, we do not leave the snake alone and marvel at the animal. We ask how to commercialise it. If mice can be made to mimic a disease state, we do not ask whether we should be manufacturing sick bodies for experimental convenience. We ask whether the effect size is promising enough for investment. According to reporting on the study, the researchers believe pTOS or a synthetic analogue could one day offer an alternative to GLP-1 drugs, which are often associated with nausea and other side effects. That possibility is exactly what makes this story so appealing to the pharmaceutical imagination. And of course there is money in that imagination.

Current GLP-1 drugs have already transformed obesity treatment and generated enormous commercial interest, while scientists are now also studying why these drugs work differently for different people. That is the backdrop for this python story: an already booming market, huge demand for “better” appetite suppressants, and a medical system primed to celebrate anything that looks like the next semaglutide.

So yes, the biology is interesting. Yes, it may teach us something real about appetite signalling. But we should be honest about what else it teaches.

It teaches that humans are still profoundly uncomfortable solving problems at their root. We would rather medicate around the edges of a broken food environment than confront the industries profiting from it. We would rather describe other animals as treasure chests of therapeutic potential than as individuals with their own lives. We would rather celebrate “nature-inspired biology” than admit how often that inspiration depends on capture, confinement, dissection, and death.

The molecule may be new. The mindset is not.

It is the same old human story: create the mess, mine another species for answers, and call the whole thing progress.